Fibroblast activation protein-targeted chimeric antigen-receptor-modified NK cells alleviate cardiac fibrosis
- Qi Zheng 1, Hao Li 1, Yongliang Jiang 2, Ping Yang 3, Gaosheng Yin 2, Lin Yang 1, Shuangxiu Li 1, Lin Sun 1
- Qi Zheng 1, Hao Li 1, Yongliang Jiang 2
- 1Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, China.
- 2Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, School of Rehabilitation, Kunming Medical University, Kunming, Yunnan 650500, China.
- 3Faculty of Basic Medical Science, Kunming Medical University, Kunming, Yunnan 650500, China.
- 0Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Engineered CAR natural killer (NK) cells targeting fibroblast activation protein (FAP) effectively reduced cardiac fibrosis in mice. This novel therapy shows promise for treating cardiovascular diseases by eliminating FAP-positive cells and improving heart function.
Area Of Science
- Immunotherapy
- Cardiovascular Research
- Cell Biology
Background
- Cardiac fibrosis (CF) is a key factor in cardiovascular disease progression, involving myofibroblast transdifferentiation.
- Fibroblast activation protein (FAP) is a specific marker for activated myofibroblasts.
- Chimeric antigen receptor (CAR)-based therapy offers a promising immunotherapy approach.
Purpose Of The Study
- To construct CAR natural killer (NK) cells targeting FAP for potential CF therapy.
- To evaluate the efficacy and mechanism of FAP-targeted CAR-NK cells in preclinical models of cardiac fibrosis.
Main Methods
- Development of FAP-specific CAR-NK-92 cells.
- In vitro assessment of FAP CAR-NK cell cytotoxicity, cytokine secretion, and degranulation against FAP+ cells and cardiac fibroblasts.
- In vivo studies using a mouse model of Ang II/PE-induced cardiac injury.
Main Results
- FAP CAR-NK-92 cells specifically recognized and killed FAP+ cells in vitro.
- Enhanced cytotoxicity, cytokine secretion, and degranulation of FAP CAR-NK cells compared to parental NK-92 cells.
- In vivo administration of FAP CAR-NK cells improved cardiac function and reduced fibrosis, with evidence of increased apoptosis in target cells.
Conclusions
- FAP CAR-NK-92 cells demonstrate specific targeting and potent anti-fibrotic effects in vitro and in vivo.
- This CAR-NK cell-based therapy represents a potential therapeutic strategy for cardiac fibrosis patients.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

